Clinical trials testing LAG-3 inhibitors in combination with programmed cell death 1 (PD-1) inhibitors have shown significant improvements in progression-free survival (PFS) compared to PD-1 inhibition alone in patients with melanoma. The gene discussed is LAG3; the disease is melanoma.